<DOC>
	<DOC>NCT00762229</DOC>
	<brief_summary>The purpose of this study is to compare the effect on LDL cholesterol levels of converting patients who are receiving the cholesterol absorption inhibitor Zetia at a dose of 10 milligrams to 5 milligrams, when prescribed as a split 10 milligram tablet.</brief_summary>
	<brief_title>Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Subjects receiving ezetimibe 10 mg Subjects who have demonstrated compliance with ezetimibe as evidenced by the following Proportions of Days Covered patterns (which represent a PDC of more than 75%): 90 day prescriptions: Filled a ezetimibe prescription within the previous 4 months 60 day prescriptions: Filled a ezetimibe prescription within the previous 2.5 months 30 day prescriptions: Filled a ezetimibe prescription within the previous 1.5 months Patients willing and able to provide signed informed consent Patients not receiving ezetimibe Patients receiving ezetimibe 5 milligrams Patients with a history of being titrated from ezetimibe 5 to 10 mg. Stroke,TIA, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass surgery, or major surgery within the 3 months Cancer undergoing active treatment Participation in any clinical study within the last 30 days Drug addiction or alcohol abuse within the past 6 months Patients unwilling or unable to provide informed consent Patients with poor compliance Women of childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Cholesterol</keyword>
	<keyword>Ezetimibe</keyword>
</DOC>